Mascara may not be the only thing that can be using to enhance eyelashes. Latisse™, a revolutionary new treatment for eyelash growth has arrived. Latisse™ was developed through years of research by Allergan, a pharmaceutical leader with over 60 years of expertise in prescription eye care products.
Beverly Hills, CA (PRWEB) February 12, 2009 -- Latisse™ (bimatoprost-ophthalmic-solution) 0.03%, approved by the U.S. Food and Drug Administration (FDA) in 2008, is a novel treatment for hypotrichosis of the eyelashes. Eyelash hypotrichosis is another name for having inadequate or not enough eyelashes. Prior to its FDA approval, Allergan conducted a 16 week clinical trial with approximately 280 volunteers to assess the safety and efficacy of Latisse™. The results exceeded expectations. Participants experienced lashes 25 percent longer, 106 percent thicker and 18 percent darker.
The story of Latisse unexpectedly began in ophthalmology offices and the treatment of glaucoma patients. A new class of medications known as prostamides had been developed to lower intraocular eye pressure and doctors noticed a surprising side effect: the prostamides also grew hair. Allergan produced Lumigan (the trade name for ophthalmic formulated bimatoprost solution) quickly became the most popular prostamide. Products such as Revitalash and Age Intervention were the first to hit the market. However, because of purported patent infringements, the makers of Age Intervention were forced to cease production. Their replacement product Marini Lash does not contain bimatoprost and as result is considered by many to be less effective than Latisse™.
"After using the product, my eyelashes really stand out. I get compliments all the time and it feels great! Everyo
'/>"/>
| Source: PRWeb Copyright©2009 Vocus, Inc. All rights reserved |